Drugs / APN1125
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02331433 | Dec 2014 → Nov 2015 | schizophrenia | CoMentis | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02724917 | Apr → Sep 2016 | schizophrenia | CoMentis | Suspended | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APN1125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02331433 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL3545013 ↗ |
| Route | Oral | “APN1125 orally at ascending doses” NCT02331433 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL3545013 ↗ |